{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:24:58Z","timestamp":1787498698736,"version":"build-2736575974"},"reference-count":97,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T00:00:00Z","timestamp":1687392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Despite the advancements in therapy for B cell malignancies and the increase in long\u2013term survival of patients, almost half of them lead to relapse. Combinations of chemotherapy and monoclonal antibodies such as anti-CD20 leads to mixed outcomes. Recent developments in immune cell-based therapies are showing many encouraging results. \u03b3\u03b4 T cells, with their potential of functional plasticity and their anti-tumoral properties, emerged as good candidates for cancer immunotherapies. The representation and the diversity of \u03b3\u03b4 T cells in tissues and in the blood, in physiological conditions or in B-cell malignancies such as B cell lymphoma, chronic lymphoblastic leukemia or multiple myeloma, provides the possibility to manipulate them with immunotherapeutic approaches for these patients. In this review, we summarized several strategies based on the activation and tumor-targeting of \u03b3\u03b4 T cells, optimization of expansion protocols, and development of gene-modified \u03b3\u03b4 T cells, using combinations of antibodies and therapeutic drugs and adoptive cell therapy with autologous or allogenic \u03b3\u03b4 T cells following potential genetic modifications.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1200003","type":"journal-article","created":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T07:40:16Z","timestamp":1687592416000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["\u03b3\u03b4 T cells in immunotherapies for B-cell malignancies"],"prefix":"10.3389","volume":"14","author":[{"given":"L\u00e9a","family":"Rimailho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Faria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Domagala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Laurent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Bezombes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Poupot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.44.12.1012","article-title":"Tissue distribution of human gamma delta T cells: no evidence for general epithelial tropism","volume":"44","author":"Vroom","year":"1991","journal-title":"J Clin Pathol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/10.8.1067","article-title":"Analysis of the TCR vgamma repertoire in healthy donors and HIV-1- infected individuals","volume":"10","author":"Wesch","year":"1998","journal-title":"Int Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830210429","article-title":"A major fraction of human intraepithelial lymphocytes simultaneously expresses the \u03b3\/\u03b4 T cell receptor, the CD8 accessory molecule and preferentially uses the V\u03b41 gene segment","volume":"21","author":"Deusch","year":"1991","journal-title":"Eur J Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3390\/ph8010040","article-title":"\u03b3\u03b4 T cell immunotherapy\u2013a review","volume":"8","author":"Kobayashi","year":"2015","journal-title":"Pharmaceuticals"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1006\/cimm.2001.1850","article-title":"Differentiation of resting human peripheral blood \u03b3\u03b4 T cells toward Th1- or Th2-phenotype","volume":"212","author":"Wesch","year":"2001","journal-title":"Cell Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.7.4304","article-title":"Distinct cytokine-driven responses of activated blood \u03b3\u03b4 T cells: insights into unconventional T cell pleiotropy","volume":"178","author":"Vermijlen","year":"2007","journal-title":"J Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1607136113","article-title":"Human V\u03b42 T cells are a major source of interleukin-9","volume":"113","author":"Peters","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-01-0331","article-title":"Fc\u03b3RIII discriminates between 2 subsets of V\u03b39V\u03b42 effector cells with different responses and activation pathways","volume":"104","author":"Angelini","year":"2004","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1818488116","article-title":"Single-cell RNA sequencing unveils the shared and the distinct cytotoxic hallmarks of human TCRV\u03b41 and TCRV\u03b42 \u03b3\u03b4 T lymphocytes","volume":"116","author":"Pizzolato","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.4161\/onci.22892","article-title":"Tumor cell recognition by \u03b3\u03b4 T lymphocytes: T-cell receptor vs","volume":"2","author":"Correia","year":"2013","journal-title":"NK-cell receptors. OncoImmunology"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21645","article-title":"Quantification and phenotypic characterization of peripheral blood V\u03b41\u2009+\u2009T cells in chronic lymphocytic leukemia and monoclonal b cell lymphocytosis","volume":"96","author":"Sim\u00f5es","year":"2019","journal-title":"Cytometry B Clin Cytom"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3083.2009.02290.x","article-title":"Toll-like receptor expression and function in subsets of human \u03b3\u03b4 T lymphocytes","volume":"70","author":"Pietschmann","year":"2009","journal-title":"Scandinavian J Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109871","article-title":"NKG2A expression identifies a subset of human V\u03b42 T cells exerting the highest antitumor effector functions","volume":"37","author":"Cazzetta","year":"2021","journal-title":"Cell Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1852473","article-title":"Clinical relevance of NKT cells and soluble MIC-a in Hodgkin lymphoma","volume":"62","author":"Vela-Ojeda","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"B15","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13027-021-00365-4","article-title":"Immunophenotypic characterization of TCR \u03b3\u03b4 T cells and MAIT cells in HIV-infected individuals developing hodgkin\u2019s lymphoma","volume":"16","author":"Muller","year":"2021","journal-title":"Infect Agent Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/241246","article-title":"The feature of distribution and clonality of TCR \u03b3\/\u03b4 subfamilies T cells in patients with b-cell non-Hodgkin lymphoma","volume":"2014","author":"Wang","year":"2014","journal-title":"J Immunol Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1321751","article-title":"Increased frequencies of circulating and tumor-resident V\u03b41+ T cells in patients with diffuse large b-cell lymphoma","volume":"59","author":"Reboursiere","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0901980","article-title":"Gammadelta T lymphocytes count is normal and expandable in peripheral blood of patients with follicular lymphoma, whereas it is decreased in tumor lymph nodes compared with inflammatory lymph nodes","volume":"184","author":"Braza","year":"2010","journal-title":"J Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1554175","article-title":"Boosting \u03b3\u03b4 T cell-mediated antibody-dependent cellular cytotoxicity by PD-1 blockade in follicular lymphoma","volume":"8","author":"Rossi","year":"2019","journal-title":"OncoImmunology"},{"key":"B20","first-page":"86","article-title":"Molecular diversity of gammadelta T cells in peripheral blood from patients with b-cell chronic lymphocytic leukaemia","volume":"49","author":"Bartkowiak","year":"2002","journal-title":"Neoplasma"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-2417","article-title":"Vdelta1 T lymphocytes from b-CLL patients recognize ULBP3 expressed on leukemic b cells and up-regulated by trans-retinoic acid","volume":"64","author":"Poggi","year":"2004","journal-title":"Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.763773","article-title":"Bone marrow-resident V\u03b41 T cells Co-express TIGIT with PD-1, TIM-3 or CD39 in AML and myeloma","volume":"8","author":"Brauneck","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"B23","doi-asserted-by":"publisher","first-page":"6960","DOI":"10.1038\/s41467-021-26951-z","article-title":"Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomics","volume":"12","author":"Tirier","year":"2021","journal-title":"Nat Commun"},{"key":"B24","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.bbrc.2016.10.098","article-title":"Characterization of \u03b3\u03b4 regulatory T cells from peripheral blood in patients with multiple myeloma","volume":"480","author":"Ma","year":"2016","journal-title":"Biochem Biophys Res Commun"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-417519","article-title":"Dysfunctional V\u03b39V\u03b42 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells","volume":"120","author":"Coscia","year":"2012","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017005447","article-title":"Immune signatures associated with improved progression-free and overall survival for myeloma patients treated with AHSCT","volume":"1","author":"Ho","year":"2017","journal-title":"Blood Adv"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1502202","article-title":"Molecular analysis of lipid-reactive V\u03b41 \u03b3\u03b4 T cells identified by CD1c tetramers","volume":"196","author":"Roy","year":"2016","journal-title":"J Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1300121","article-title":"Cutting edge: CD1d restriction and Th1\/Th2\/Th17 cytokine secretion by human V\u03b43 T cells","volume":"191","author":"Mangan","year":"2013","journal-title":"J Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2004.06.013","article-title":"Non-peptide antigens activating human V\u03b39\/V\u03b42 T lymphocytes","volume":"95","author":"Poupot","year":"2004","journal-title":"Immunol Lett"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1126\/science.aay5516","article-title":"Butyrophilin 2A1 is essential for phosphoantigen reactivity by \u03b3\u03b4 T cells","volume":"367","author":"Rigau","year":"2020","journal-title":"Science"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-007-9004-4","article-title":"Anti-tumor cytotoxicity of gammadelta T cells expanded from peripheral blood cells of patients with myeloma and lymphoma","volume":"25","author":"Saitoh","year":"2008","journal-title":"Med Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.097311","article-title":"Aminobisphosphonates prevent the inhibitory effects exerted by lymph node stromal cells on anti-tumor v\u03b4 2 T lymphocytes in non-Hodgkin lymphomas","volume":"99","author":"Musso","year":"2014","journal-title":"Haematologica"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-430470","article-title":"Key implication of CD277\/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human \u03b3\u03b4 T-cell subset","volume":"120","author":"Harly","year":"2012","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1401064","article-title":"Activation of human \u03b3\u03b4 T cells by cytosolic interactions of BTN3A1 with soluble phosphoantigens and the cytoskeletal adaptor periplakin","volume":"194","author":"Rhodes","year":"2015","journal-title":"J Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2016.04.081","article-title":"RhoB mediates phosphoantigen recognition by V\u03b39V\u03b42 T cell receptor","volume":"15","author":"Sebestyen","year":"2016","journal-title":"Cell Rep"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00508","article-title":"V\u03b39V\u03b42 T cells as strategic weapons to improve the potency of immune checkpoint blockade and immune interventions in human myeloma","volume":"8","author":"Castella","year":"2018","journal-title":"Front Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1701237115","article-title":"Heteromeric interactions regulate butyrophilin (BTN) and BTN-like molecules governing \u03b3\u03b4 T cell biology","volume":"115","author":"Vantourout","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2013.00069","article-title":"Natural cytotoxicity receptors: broader expression patterns and functions in innate and adaptive immune cells","volume":"4","author":"Hudspeth","year":"2013","journal-title":"Front Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.12.6336","article-title":"Synaptic transfer by human \u03b3\u03b4 T cells stimulated with soluble or cellular antigens","volume":"168","author":"Espinosa","year":"2002","journal-title":"J Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.3.1717","article-title":"Profiling blood lymphocyte interactions with cancer cells uncovers the innate reactivity of human \u03b3\u03b4 T cells to anaplastic Large cell lymphoma","volume":"174","author":"Poupot","year":"2005","journal-title":"J Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/nri2781","article-title":"\u03b3\u03b4 T cell effector functions: a blend of innate programming and acquired plasticity","volume":"10","author":"Bonneville","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403693","article-title":"Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma","volume":"19","author":"Mariani","year":"2005","journal-title":"Leukemia"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1002514","article-title":"Immune modulation by zoledronic acid in human myeloma: an advantageous cross-talk between V\u03b39V\u03b42 T cells, \u03b1\u03b2 CD8+ T cells, regulatory T cells, and dendritic cells","volume":"187","author":"Castella","year":"2011","journal-title":"J Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-12-822569","article-title":"Improving CLL V\u03b39V\u03b42-t-cell fitness for cellular therapy by ex vivo activation and ibrutinib","volume":"132","author":"de Weerdt","year":"2018","journal-title":"Blood"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.13979","article-title":"Low-dose bortezomib increases the expression of NKG2D and DNAM-1 ligands and enhances induced NK and \u03b3\u03b4 T cell-mediated lysis in multiple myeloma","volume":"8","author":"Niu","year":"2017","journal-title":"Oncotarget"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3109\/14653249.2012.700766","article-title":"Human Vdelta1 gamma-delta T cells exert potent specific cytotoxicity against primary multiple myeloma cells","volume":"14","author":"Knight","year":"2012","journal-title":"Cytotherapy"},{"key":"B47","doi-asserted-by":"publisher","first-page":"e1123367","DOI":"10.1080\/2162402X.2015.1123367","article-title":"ADAM10 new selective inhibitors reduce NKG2D ligand release sensitizing Hodgkin lymphoma cells to NKG2D-mediated killing","volume":"5","author":"Zocchi","year":"2016","journal-title":"Oncoimmunology"},{"key":"B48","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nri3384","article-title":"Six-of-the-best: unique contributions of \u03b3\u03b4 T cells to immunology","volume":"13","author":"Vantourout","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.894580","article-title":"Contemplating dichotomous nature of gamma delta T cells for immunotherapy","volume":"13","author":"Bhat","year":"2022","journal-title":"Front Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.37349\/ei.2022.00054","article-title":"Allogeneic gamma delta T cells as adoptive cellular therapy for hematologic malignancie","volume":"2","author":"Jhita","year":"2022","journal-title":"Explor Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14123005","article-title":"Human \u03b3\u03b4 T cell subsets and their clinical applications for cancer immunotherapy","volume":"14","author":"Lee","year":"2022","journal-title":"Cancers"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.915837","article-title":"Gamma delta T-cell based cancer immunotherapy: past-Present-Future","volume":"13","author":"Saura-Esteller","year":"2022","journal-title":"Front Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00722-1","article-title":"The emerging roles of \u03b3\u03b4 T cells in cancer immunotherapy","volume":"20","author":"Mensurado","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-0599","article-title":"Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase Kinase-3\u2013dependent expression of MHC class I\u2013related chain a and b","volume":"65","author":"Skov","year":"2005","journal-title":"Cancer Res"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01615","article-title":"Checkpoint blockade rescues the repressive effect of histone deacetylases inhibitors on \u03b3\u03b4 T cell function","volume":"9","author":"Bhat","year":"2018","journal-title":"Front Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00569","article-title":"Histone deacetylase inhibitor modulates NKG2D receptor expression and memory phenotype of human Gamma\/Delta T cells upon interaction with tumor cells","volume":"10","author":"Bhat","year":"2019","journal-title":"Front Immunol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/sji.12581","article-title":"CD20-specific immunoligands engaging NKG2D enhance \u03b3\u03b4 T cell-mediated lysis of lymphoma cells","volume":"86","author":"Peipp","year":"2017","journal-title":"Scand J Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.2.384","article-title":"Stimulation of \u03b3\u03b4 T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma","volume":"96","author":"Kunzmann","year":"2000","journal-title":"Blood"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-010-9434-1","article-title":"Coculturing dendritic cells with zoledronate acid efficiently enhance the anti-tumor effects of cytokine-induced killer cells","volume":"30","author":"Su","year":"2010","journal-title":"J Clin Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.573156","article-title":"Phase II trial of maintenance treatment with IL2 and zoledronate in multiple myeloma after bone marrow transplantation: biological and clinical results","volume":"11","author":"Fazzi","year":"2020","journal-title":"Front Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-12-3665","article-title":"\u03b3\u03b4 T cells for immune therapy of patients with lymphoid malignancies","volume":"102","author":"Wilhelm","year":"2003","journal-title":"Blood"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-08-172296","article-title":"Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies","volume":"113","author":"Gertner-Dardenne","year":"2009","journal-title":"Blood"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V114.22.1649.1649","article-title":"Phase I\/II study of IPH1101, \u03b3\u03c3 T cell agonist, combined with rituximab, in low grade follicular lymphoma patients","volume":"114","author":"Laurent","year":"2009","journal-title":"Blood"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e318245bb1e","article-title":"Tumor-promoting versus tumor-antagonizing roles of \u03b3\u03b4 T cells in cancer immunotherapy: results from a prospective phase I\/II trial","volume":"35","author":"Kunzmann","year":"2012","journal-title":"J Immunotherapy"},{"key":"B65","doi-asserted-by":"publisher","first-page":"e1216291","DOI":"10.1080\/2162402X.2016.1216291","article-title":"Zoledronic acid boosts \u03b3\u03b4 T-cell activity in children receiving \u03b1\u03b2 + T and CD19 + cell-depleted grafts from an HLA-haplo-identical donor","volume":"6","author":"Bertaina","year":"2017","journal-title":"OncoImmunology"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00699","article-title":"Immune modulation properties of zoledronic acid on TcR\u03b3\u03b4 T-lymphocytes after TcR\u03b1\u03b2\/CD19-depleted haploidentical stem cell transplantation: an analysis on 46 pediatric patients affected by acute leukemia","volume":"11","author":"Merli","year":"2020","journal-title":"Front Immunol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abj0835","article-title":"Development of ICT01, a first-in-class, anti-BTN3A antibody for activating V\u03b39V\u03b42 T cell\u2013mediated antitumor immune response","volume":"13","author":"De Gassart","year":"2021","journal-title":"Sci Transl Med"},{"key":"B68","doi-asserted-by":"publisher","first-page":"e1047580","DOI":"10.1080\/2162402X.2015.1047580","article-title":"Anergic bone marrow V\u03b39V\u03b42 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma","volume":"4","author":"Castella","year":"2015","journal-title":"Oncoimmunology"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01492","article-title":"V\u03b39V\u03b42 T cells in the bone marrow of myeloma patients: a paradigm of microenvironment-induced immune suppression","volume":"9","author":"Castella","year":"2018","journal-title":"Front Immunol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.23365","article-title":"V Gamma 9 V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs\u2013rituximab and trastuzumab","volume":"122","author":"Tokuyama","year":"2008","journal-title":"Int J Cancer"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.029520","article-title":"\u03b3\u03b4 T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody","volume":"96","author":"Braza","year":"2011","journal-title":"Haematologica"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000289","article-title":"Improving immunotherapy against b-cell malignancies using \u03b3\u03b4 T-cell-specific stimulation and therapeutic monoclonal antibodies","volume":"42","author":"Hoeres","year":"2019","journal-title":"J Immunother"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.13110","article-title":"CD19-specific triplebody SPM-1 engages NK and \u03b3\u03b4 T cells for rapid and efficient lysis of malignant b-lymphoid cells","volume":"7","author":"Schiller","year":"2016","journal-title":"Oncotarget"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1158\/1078-0432.CCR-20-4576","article-title":"Abispecific single-domain antibody boosts autologous Vg9Vd2-T cell responses towardCD1d in chronic lymphocytic leukemia","volume":"27","author":"de Weerdt","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B75","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1158\/2326-6066.CIR-20-0138","article-title":"A bispecific antibody antagonizes prosurvival CD40 signaling and promotes V\u03b39V\u03b42 T cell-mediated antitumor responses in human b-cell malignancies","volume":"9","author":"de Weerdt","year":"2021","journal-title":"Cancer Immunol Res"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003850","article-title":"Gamma delta TCR anti-CD3 bispecific molecules (GABs) as novel immunotherapeutic compounds","volume":"9","author":"van Diest","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.100961","article-title":"A bispecific T cell engager recruits both type 1 NKT and V?9V\u03b42-T cells for the treatment of CD1d-expressing hematological malignancies","volume":"4","author":"Lameris","year":"2023","journal-title":"Cell Rep Med"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3390\/cells11223572","article-title":"Human V\u03b42 T cells and their versatility for immunotherapeutic approaches","volume":"11","author":"Sanz","year":"2022","journal-title":"Cells"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2009.04.008","article-title":"Clinical and immunological evaluation of zoledronate-activated V\u03b39\u03b3\u03b4 T-cell-based immunotherapy for patients with multiple myeloma","volume":"37","author":"Abe","year":"2009","journal-title":"Exp Hematol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40425-019-0501-8","article-title":"Allogenic V\u03b39V\u03b42 T cell as new potential immunotherapy drug for solid tumor: a case study for cholangiocarcinoma","volume":"7","author":"Alnaggar","year":"2019","journal-title":"J immunotherapy Cancer"},{"key":"B81","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41392-020-00260-1","article-title":"Irreversible electroporation plus allogenic V\u03b39V\u03b42 T cells enhances antitumor effect for locally advanced pancreatic cancer patients","volume":"5","author":"Lin","year":"2020","journal-title":"Sig Transduct Target Ther"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0515-7","article-title":"Allogeneic V\u03b39V\u03b42 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer","volume":"18","author":"Xu","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-12-45","article-title":"Successful adoptive transfer and in vivo expansion of haploidentical \u03b3\u03b4 T cells","volume":"12","author":"Wilhelm","year":"2014","journal-title":"J Transl Med"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0597","article-title":"Delta one T cells for immunotherapy of chronic lymphocytic leukemia: clinical-grade Expansion\/Differentiation and preclinical proof of concept","volume":"22","author":"Almeida","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05077.x","article-title":"Human \u03b3\u03b4 T cells as mediators of chimaeric-receptor redirected anti-tumour immunity: tumour targeting with gene-modified human \u03b3\u03b4 T cells","volume":"126","author":"Rischer","year":"2004","journal-title":"Br J Haematology"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2012.267","article-title":"Bispecific T-cells expressing polyclonal repertoire of endogenous \u03b3\u03b4 T-cell receptors and introduced CD19-specific chimeric antigen receptor","volume":"21","author":"Deniger","year":"2013","journal-title":"Mol Ther"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01347","article-title":"Gamma-delta CAR-T cells show CAR-directed and independent activity against leukemia","volume":"11","author":"Rozenbaum","year":"2020","journal-title":"Front Immunol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.863155","article-title":"A simple and robust single-step method for CAR-V\u03b41 \u03b3\u03b4T cell expansion and transduction for cancer immunotherapy","volume":"13","author":"Ferry","year":"2022","journal-title":"Front Immunol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1373","article-title":"Allogeneic CD20-targeted \u03b3\u03b4 T cells exhibit innate and adaptive antitumor activities in preclinical b-cell lymphoma models","volume":"11","author":"Nishimoto","year":"2022","journal-title":"Clin Transl Immunol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-157400","article-title":"A phase 1 study of ADI-001: anti-CD20 CAR-engineered allogeneic gamma Delta1 (\u03b3\u03b4) T cells in adults with b-cell malignancies","volume":"140","author":"Neelapu","year":"2022","journal-title":"Blood"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005400","article-title":"Generation and proof-of-concept for allogeneic CD123 CAR-Delta One T (DOT) cells in acute myeloid leukemia","volume":"10","author":"S\u00e1nchez Mart\u00ednez","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0038-z","article-title":"Translating gammadelta (\u03b3\u03b4) T cells and their receptors into cancer cell therapies","volume":"19","author":"Sebestyen","year":"2020","journal-title":"Nat Rev Drug Discovery"},{"key":"B93","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s40425-019-0558-4","article-title":"Evaluating in vivo efficacy \u2013 toxicity profile of TEG001 in humanized mice xenografts against primary human AML disease and healthy hematopoietic cells","volume":"7","author":"Johanna","year":"2019","journal-title":"J immunotherapy Cancer"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-325993","article-title":"Redirecting \u03b1\u03b2T cells against cancer cells by transfer of a broadly tumor-reactive \u03b3\u03b4T-cell receptor","volume":"118","author":"Marcu-Malina","year":"2011","journal-title":"Blood"},{"key":"B95","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41421-018-0066-6","article-title":"A novel antibody-TCR (AbTCR) platform combines fab-based antigen recognition with gamma\/delta-TCR signaling to facilitate T-cell cytotoxicity with low cytokine release","volume":"4","author":"Xu","year":"2018","journal-title":"Cell Discovery"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01402-y","article-title":"Novel CD19-specific \u03b3\/\u03b4 TCR-T cells in relapsed or refractory diffuse large b-cell lymphoma","volume":"16","author":"Li","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0647","article-title":"Broad cytotoxic targeting of acute myeloid leukemia by polyclonal delta one T cells","volume":"7","author":"Di Lorenzo","year":"2019","journal-title":"Cancer Immunol Res"}],"updated-by":[{"DOI":"10.3389\/fimmu.2026.1933915","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000}}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1200003\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T09:50:48Z","timestamp":1786960248000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1200003\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,22]]},"references-count":97,"alternative-id":["10.3389\/fimmu.2023.1200003"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1200003","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,22]]},"article-number":"1200003"}}